NCT05412446View on ClinicalTrials.gov

99mTc-ADAPT6 SPECT-based Non-invasive Quantification of HER2-expression in Breast Cancer With Metastatic Lymph Nodes

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 1, 2022

Primary Completion Date

December 31, 2022

Study Completion Date

December 31, 2022

Conditions
Breast CancerFemale
Interventions
DRUG

ADAPT6-SPECT

Diagnostic SPECT for HER2 expression in primary tumour and metastatic lymph nodes

Trial Locations (1)

Unknown

Tomsk NRMC, Tomsk

All Listed Sponsors
collaborator

Uppsala University

OTHER

lead

Tomsk National Research Medical Center of the Russian Academy of Sciences

OTHER